Evidence map›Paper›PMID 31244811›Full record

ArticleFrontiers in microbiology2019

TRAF3 Is Required for NF-κB Pathway Activation Mediated by HTLV Tax Proteins.

Stefania Fochi, Elisa Bergamo, Michela Serena, Simona Mutascio, Chloé Journo, Renaud Mahieux, Vincenzo Ciminale, Umberto Bertazzoni, Donato Zipeto, Maria Grazia Romanelli

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Novel approaches for HTLV-1 therapy: innovative applications of CRISPR-Cas9.Revista do Instituto de Medicina Tropical de Sao Paulo · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Roles of TRAFs in Ischemia-Reperfusion Injury.Frontiers in cell and developmental biology · 2020
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Stefania FochiDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Elisa BergamoDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Michela SerenaDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Simona MutascioDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Chloé JournoRetroviral Oncogenesis Laboratory, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111 - Université Claude Bernard Lyon 1, CNRS, Equipe Labellisée "Fondation pour la Recherche Médicale", UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France.
Renaud MahieuxRetroviral Oncogenesis Laboratory, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111 - Université Claude Bernard Lyon 1, CNRS, Equipe Labellisée "Fondation pour la Recherche Médicale", UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France.
Vincenzo CiminaleDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Umberto BertazzoniDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Donato ZipetoDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
Maria Grazia RomanelliDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy.
University of Verona · ITCentre International de Recherche en Infectiologie · FRÉcole Normale Supérieure de Lyon · FRIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human T-cell leukemia viruses type 1 (HTLV-1) and type 2 (HTLV-2) share a common genome organization and expression strategy but have distinct pathological properties. HTLV-1 is the etiological agent of Adult T-cell Leukemia (ATL) and of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), whereas HTLV-2 does not cause hematological disorders and is only sporadically associated with cases of subacute myelopathy. Both HTLV genomes encode two regulatory proteins that play a pivotal role in pathogenesis: the transactivating Tax-1 and Tax-2 proteins and the antisense proteins HBZ and APH-2, respectively. We recently reported that Tax-1 and Tax-2 form complexes with the TNF-receptor associated factor 3, TRAF3, a negative regulator of the non-canonical NF-κB pathway. The NF-κB pathway is constitutively activated by the Tax proteins, whereas it is inhibited by HBZ and APH-2. The antagonistic effects of Tax and antisense proteins on NF-κB activation have not yet been fully clarified. Here, we investigated the effect of TRAF3 interaction with HTLV regulatory proteins and in particular its consequence on the subcellular distribution of the effector p65/RelA protein. We demonstrated that Tax-1 and Tax-2 efficiency on NF-κB activation is impaired in TRAF3 deficient cells obtained by CRISPR/Cas9 editing. We also found that APH-2 is more effective than HBZ in preventing Tax-dependent NF-κB activation. We further observed that TRAF3 co-localizes with Tax-2 and APH-2 in cytoplasmic complexes together with NF-κB essential modulator NEMO and TAB2, differently from HBZ and TRAF3. These results contribute to untangle the mechanism of NF-κB inhibition by HBZ and APH-2, highlighting the different role of the HTLV-1 and HTLV-2 regulatory proteins in the NF-κB activation.

Indexed as

APH-2HBZHTLVNF-κBTaxTRAF3

Identifiers

PMID31244811
PMCPMC6581700
OpenAlexW2952687284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.